British Menopause Society tools for clinicians: Progestogens and endometrial protection
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Progestogen administration is required to oppose naturally produced or administered estrogens to provide endometrial protection. Within HRT regimens, this should be delivered for at least the same duration as that produced during the luteal phase of the monthly cycle and in the recommended doses to protect against the risk of endometrial hyperplasia and endometrial cancer. This includes progestogens administered for 12–14 days a month in sequential regimens and continuous daily intake in continuous combined HRT regimens. Shorter durations and lower doses of progestogen intake are likely to be associated with an increased risk of breakthrough bleeding, endometrial hyperplasia, and endometrial cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, optimal HRT in young women who have undergone pelvic clearance for endometriosis remains uncertain.”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [9]
In the citing paper
“This has led the British Menopause Society (BMS) and European Society of Human Reproduction and Embryology (ESHRE) to recommend continuous C-HRT and avoidance of EO-HRT in this group of women at least until age of natural menopause [9,10].”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [9]
In the citing paper
“The recent guidelines of both BMS and ESHRE acknowledge the limited evidence with regard to the optimal HRT regimen in women with endometriosis.”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [9]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens
Ziel, H. K., & Finkle, W. D. (1975) · New England Journal of Medicine · doi:10.1056/nejm197512042932303 · Cited by 1,008
Association of Exogenous Estrogen and Endometrial Carcinoma
Smith, D. C., Prentice, R., Thompson, D. J., & Herrmann, W. L. (1975) · New England Journal of Medicine · doi:10.1056/nejm197512042932302 · Cited by 960
Estrogens and Endometrial Cancer in a Retirement Community
Mack, T. M., Pike, M. C., Henderson, B. E., Pfeffer, R. I., Gerkins, V. R., Arthur, M., & Brown, S. E. (1976) · New England Journal of Medicine · doi:10.1056/nejm197606032942304 · Cited by 557
Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins
Weiderpass, E., Adami, H.-O., Baron, J. A., Magnusson, C., Bergstrom, R., Lindgren, A., Correia, N., & Persson, I. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.13.1131 · Cited by 471
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192 · cited 15×
“The absorption of the latter is variable with fluctuating tissue availability and as a result may not provide sufficient endometrial protection.(25,2)”
BackgroundSelf-citationHormone therapy in postmenopausal women and risk of endometrial hyperplasia
Furness, S., Roberts, H., Marjoribanks, J., & Lethaby, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000402.pub4 · Cited by 173
The management of menopause in women with a history of endometriosis: A systematic review
Gemmell, L. C., Webster, K. E., Kirtley, S., Vincent, K., Zondervan, K. T., & Becker, C. M. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx011 · Cited by 154 · cited 1×
“However, there is limited evidence available on this to guide clinical practice.(27,28)”
BackgroundAssessment of the potency of orally administered progestins in women
King, R. J. B., & Whitehead, M. I. (1986) · Fertility and Sterility · doi:10.1016/s0015-0282(16)49880-8 · Cited by 124
The impact of micronized progesterone on the endometrium: a systematic review
Stute, P., Neulen, J., & Wildt, L. (2016) · Climacteric · doi:10.1080/13697137.2016.1187123 · Cited by 109 · cited 6×
“Forty studies were included in the systematic review and it concluded that oral micronized progesterone provides endometrial protection if applied sequentially for 12– 14 days/month in a dose of 200 mg/day for up to five years.(18) Based on current evidence, progestogen intake in nonhysterectomized women taking sequen…”
BackgroundMethodInfluentialProgesterone and endometrial cancer
Gompel, A. (2020) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.05.003 · Cited by 102
Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium.
Lane, G., Siddle, N. C., Ryder, T. A., Pryse-Davies, J., King, R. J., & Whitehead, M. I. (1983) · BMJ · doi:10.1136/bmj.287.6401.1241 · Cited by 100
Varila, E., Wahlström, T., & Rauramo, I. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)02846-1 · Cited by 76
Doherty, J. A., Cushing‐Haugen, K. L., Saltzman, B. S., Voigt, L. F., Hill, D. A., Beresford, S. A. A., Chen, C., & Weiss, N. S. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.01.019 · Cited by 72
Hampton, N. R. E., Rees, M. C. P., Lowe, D. G., Rauramo, I., Barlow, D., & Guillebaud, J. (2005) · Human Reproduction · doi:10.1093/humrep/dei085 · Cited by 72
Hormone replacement therapy in women with past history of endometriosis
Soliman, N. F., & Hillard, T. C. (2006) · Climacteric · doi:10.1080/13697130600868711 · Cited by 65 · cited 1×
“However, there is limited evidence available on this to guide clinical practice.(27,28)”
BackgroundSuvanto‐Luukkonen, E., & Kauppila, A. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00162-4 · Cited by 56
Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer
Reed, S. D., Voigt, L. F., Beresford, S. A. A., Hill, D. A., Doherty, J. A., & Weiss, N. S. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.04.041 · Cited by 29
Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns
Carlo, C. D., Tommaselli, G. A., Gargano, V., Savoia, F., Bifulco, G., & Nappi, C. (2010) · Climacteric · doi:10.3109/13697137.2010.490605 · Cited by 29
Postmenopausal vaginal bleeding in women using hormone replacement therapy
Burbos, N., Musonda, P., Duncan, T. J., Crocker, S. G., Nieto, J. J., & Morris, E. (2012) · Menopause international · doi:10.1258/mi.2011.011111 · Cited by 24
Saure, A., Hirvonen, E., Tikkanen, M. J., Viinikka, L. U., & Ylikorkala, O. (1993) · Maturitas · doi:10.1016/0378-5122(93)90128-5 · Cited by 22
Saure, A., Planellas, J., Poulsen, H., & Jaszczak, P. (2000) · Maturitas · doi:10.1016/s0378-5122(99)00103-6 · Cited by 21
Hormone replacement therapy after transcervical resection of the endometrium
Istre, O., Holm-Nielsen, P., Bourne, T., & Forman, A. (1996) · Obstetrics and Gynecology · doi:10.1016/0029-7844(96)00308-0 · Cited by 19 · cited 12×
“The Mirena IUS has a four-year license in the UK for progestogenic opposition of estrogen HRT. Studies have shown it to be effective and to offer sufficient endometrial protection up to five years within HRT regimens.”
MethodInfluentialUterine bleeding with hormone therapies in menopausal women: a systematic review
Pickar, J. H., Archer, D. F., Goldstein, S. R., Kagan, R., Bernick, B. A., & Mirkin, S. (2020) · Climacteric · doi:10.1080/13697137.2020.1806816 · Cited by 18
Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women
Sriprasert, I., Mert, M., Mack, W. J., Hodis, H. N., & Shoupe, D. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.09.002 · Cited by 15 · cited 2×
“The authors concluded that 10 days of vaginal progesterone 45 mg/day is insufficient to completely oppose the effect of oral estradiol 1 mg/day on the endometrium.(20) More evidence in adequately powered studies is required to assess the optimal dose and duration of vaginal progesterone intake to provide optimal endom…”
BackgroundMethodBMS – Consensus statement: Bioidentical HRT
Panay, N., & in collaboration with the Medical Advisory Council of the British Menopause Society (2019) · Post Reproductive Health · doi:10.1177/2053369119841844 · Cited by 14 · cited 2×
“conventional HRT and as such the use of such compounded products is not recommended.(25,2) There are concerns related to the purity, potency, and safety of compounded products and there is lack of evidence to suggest that the dosage of progesterone used in compounded preparations provides sufficient endometrial protec…”
BackgroundOutcomes of endometrial assessment in women with unscheduled bleeding on hormone replacement therapy
Idle, S. A., & Hamoda, H. (2019) · Post Reproductive Health · doi:10.1177/2053369119830822 · Cited by 6
Self-citationManagement of women requesting subtotal hysterectomy
Maina, W. C., & Morris, E. (2010) · Menopause international · doi:10.1258/mi.2010.010038 · Cited by 5
Research works printed but not linked: 4
- Gambrell RD, 1977, J Reprod Med, 18, 301e6
- Berger GS, 1977, J ReprodMed, 18, 177e80
- Bednarek PH, 2009, Int J Women’s Health, 1, 45
- Intercollegiate Guidelines Network, 2002, Investigation of Postmenopausal Bleeding, a National Clinical Guideline
Cited by
Management of perimenopausal and menopausal symptoms
Duralde, E. R., Sobel, T. H., & Manson, J. E. (2023) · BMJ · doi:10.1136/bmj-2022-072612 · Cited by 161
Panay, N., Ang, S. B., Cheshire, R., Goldstein, S. R., Maki, P. M., Nappi, R. E., & on behalf of the International Menopause Society Board (2024) · Climacteric · doi:10.1080/13697137.2024.2394950 · Cited by 134
“…promptly as previously described. if the dose of estrogen is increased it is important that the dose of progestogen is also increased proportionately to provide sufficient endometrial protection, although there is little evidence from women using higher doses outside the product license [73].”
BackgroundTaylor, A., Clement, K., Hillard, T., Sassarini, J., Ratnavelu, N. D., Baker-Rand, H. L. A., Bowen, R. L., Davies, M. C., Edey, K., Fernandes, A. S., et al. (2024) · Post Reproductive Health · doi:10.1177/20533691241286666 · Cited by 37
“75,76 Observational and case control data suggest that micronised progesterone may reduce the increased risk of VTE conferred by oral estrogen, compared to that noted with synthetic progestins.”
Manley, K., Hillard, T., Clark, T. J., Kumar, G., Morrison, J., Hamoda, H., Barber, K., Holloway, D., Middleton, B., Oyston, M., et al. (2024) · Post Reproductive Health · doi:10.1177/20533691241254413 · Cited by 25
Self-citationHRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey
Amer, S., & Bazmi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010336 · Cited by 11
Metadata
- Authors
- Hamoda, H., & on behalf of the BMS medical advisory council
- Affiliations
- King's College Hospital (GB)
- Corresponding author
- Hamoda, Haitham
- ORCID
- Hamoda, Haitham
- Venue
- Post Reproductive Health
- Publisher
- Informa UK Limited
- Published
- 2021-11-27
- Volume
- 28
- Issue
- 1
- Pages
- 40-46
- ISSN
- 2053-3370 (ISSN-L)
- 2053-3691
- 2053-3705
- OpenAlex
- W3217033443
- Cited by
- 23
- References
- 30
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 2
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Post Reproductive Health (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- progestogens, endometrial protection, hormone replacement therapy, menopause, endometrial hyperplasia, endometrial cancer, breakthrough bleeding
- MeSH terms
- Endometrial Hyperplasia, Endometrium, Estrogens, Female, Humans, Menopause, Progestins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.